Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 9:23 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 2,267 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Ovary Disease Clear all
Completed Phase 1 Interventional

Gene Therapy in Treating Patients With Advanced Recurrent or Persistent Ovarian Cancer or Primary Peritoneal Cancer

NCT00003450
View directory record Official record
Conditions
Ovarian Cancer, Peritoneal Cavity Cancer
Interventions
Ad5CMV-p53 gene
Biological
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 120 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 1999
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 2, 2021 · Synced Oct 20, 2026, 9:23 PM EDT
Terminated Phase 2 Interventional

A Phase 2, Single-Arm Study of Volociximab Monotherapy in Subjects With Platinum-Resistant Advanced Epithelial Ovarian Cancer or Primary Peritoneal Cancer

NCT00516841
View directory record Official record
Conditions
Ovarian Cancer, Peritoneal Neoplasms
Interventions
Volociximab
Drug
Lead sponsor
Facet Biotech
Industry
Eligibility
18 Years and older · Female only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
19
States / cities
Los Angeles, California • Orange, California • San Diego, California + 13 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2012 · Synced Oct 20, 2026, 9:23 PM EDT
Terminated Phase 1 Interventional

Combination Chemotherapy Consisting of Gemcitabine And Topotecan in Treating Patients With Refractory or Recurrent Ovarian or Fallopian Tube Cancer

NCT00003382
View directory record Official record
Conditions
Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
Interventions
filgrastim, gemcitabine hydrochloride, topotecan hydrochloride
Biological · Drug
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
6
States / cities
Los Gatos, California • Orange, California • Palo Alto, California + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2013 · Synced Oct 20, 2026, 9:23 PM EDT
Completed Phase 1Phase 2 Interventional

Chemotherapy in Treating Patients With Solid Tumors

NCT00003103
View directory record Official record
Conditions
Bladder Cancer, Breast Cancer, Colorectal Cancer, Esophageal Cancer, Head and Neck Cancer, Kidney Cancer, Lung Cancer, Ovarian Cancer, Prostate Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
oblimersen sodium, docetaxel
Biological · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2002
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 3, 2013 · Synced Oct 20, 2026, 9:23 PM EDT
Completed Phase 1 Interventional

Phase IB Trial of LDE225 and Paclitaxel in Recurrent Ovarian Cancer

NCT02195973
View directory record Official record
Conditions
Recurrent Ovarian Cancer
Interventions
LDE225
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older · Female only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Oct 20, 2026, 9:23 PM EDT
Not listed Phase 1 Interventional

Dose Escalation of RMC-4630 Monotherapy in Relapsed/Refractory Solid Tumors

NCT03634982
View directory record Official record
Conditions
Solid Tumors
Interventions
RMC-4630
Drug
Lead sponsor
Revolution Medicines, Inc.
Industry
Eligibility
18 Years and older
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
12
States / cities
Scottsdale, Arizona • Duarte, California • Orange, California + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2022 · Synced Oct 20, 2026, 9:23 PM EDT
Completed No phase listed Observational

The Longitudinal Ovarian Reserve Study

NCT02395341
View directory record Official record
Conditions
Effects of Chemotherapy
Interventions
Not listed
Lead sponsor
University of Pennsylvania
Other
Eligibility
15 Years to 45 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • Radnor, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 22, 2016 · Synced Oct 20, 2026, 9:23 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Topotecan and Gefitinib (Iressa) for Ovarian, Peritoneal, or Fallopian Tube Cancer

NCT00317772
View directory record Official record
Conditions
Ovarian Cancer, Peritoneal Neoplasms, Fallopian Tube Cancer
Interventions
Topotecan, Gefitinib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Female only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 7, 2022 · Synced Oct 20, 2026, 9:23 PM EDT
Completed Phase 1 Interventional

A Study of ZYC300 Administered With Cyclophosphamide Pre-Dosing

NCT00381173
View directory record Official record
Conditions
Breast Cancer, Ovarian Cancer, Prostate Cancer, Colon Cancer, Renal Cancer
Interventions
Cyclophosphamide & ZYC300 (ZYC300 with cyclophosphamide pre-dosing)
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
2
States / cities
Boston, Massachusetts • Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 14, 2013 · Synced Oct 20, 2026, 9:23 PM EDT
Terminated Not applicable Interventional

Lactobacillus in Preventing Infection in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer or Myelodysplastic Syndrome

NCT00946283
View directory record Official record
Conditions
Breast Cancer, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Neuroblastoma, Ovarian Cancer, Testicular Germ Cell Tumor
Interventions
Lactobacillus rhamnosus GG
Dietary Supplement
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years to 120 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 3, 2017 · Synced Oct 20, 2026, 9:23 PM EDT
Not listed Phase 2 Interventional Results available

Paclitaxel and Carboplatin or Bleomycin Sulfate, Etoposide Phosphate, and Cisplatin in Treating Patients With Advanced or Recurrent Sex Cord-Ovarian Stromal Tumors

NCT01042522
View directory record Official record
Conditions
Ovarian Granulosa Cell Tumor, Ovarian Gynandroblastoma, Ovarian Sertoli-Leydig Cell Tumor, Ovarian Sex Cord Tumor With Annular Tubules, Ovarian Sex Cord-Stromal Tumor, Ovarian Sex Cord-Stromal Tumor, Not Otherwise Specified, Ovarian Steroid Cell Tumor
Interventions
Bleomycin Sulfate, Carboplatin, Cisplatin, Etoposide Phosphate, Laboratory Biomarker Analysis, Paclitaxel
Biological · Drug · Other
Lead sponsor
GOG Foundation
Network
Eligibility
18 Years and older · Female only
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2022
U.S. locations
219
States / cities
Anchorage, Alaska • Burbank, California • Sylmar, California + 156 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2022 · Synced Oct 20, 2026, 9:23 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of Catumaxomab to Treat Ovarian Cancer After a Complete Response to Chemotherapy

NCT00377429
View directory record Official record
Conditions
Ovarian Cancer
Interventions
catumaxomab
Drug
Lead sponsor
Neovii Biotech
Industry
Eligibility
18 Years and older · Female only
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
12
States / cities
Tucson, Arizona • Stanford, California • Orlando, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2012 · Synced Oct 20, 2026, 9:23 PM EDT
Recruiting Phase 1 Interventional

Infusion of Autologous T Cells Engineered to Target FSH Receptor in Recurrent Ovarian Cancer

NCT05316129
View directory record Official record
Conditions
Ovarian Cancer
Interventions
Follicle Stimulating Hormone Receptor T Cells
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 20, 2026, 9:23 PM EDT
Completed Phase 3 Interventional

Treatment of Infertility in Women With Polycystic Ovary Syndrome

NCT00068861
View directory record Official record
Conditions
Polycystic Ovary Syndrome, Infertility, Pregnancy
Interventions
metformin XR, clomiphene citrate
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
18 Years to 39 Years · Female only
Enrollment
678 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
11
States / cities
Birmingham, Alabama • La Jolla, California • Stanford, California + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2007 · Synced Oct 20, 2026, 9:23 PM EDT
Not yet recruiting No phase listed Observational Accepts healthy volunteers

Analysis of Breath Volatile Organic Compounds Using Mass Spectrometry

NCT07732686
View directory record Official record
Conditions
Pancreas Cancer, Hepatocellular Carcinoma, Lung Cancer, Ovarian Cancer, Breast Cancer, Head and Neck Cancer, Colon Cancer, Bladder Cancer, Other Cancer
Interventions
Proton Transfer Reaction Mass Spectrometry Analysis
Device
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 20, 2026, 9:23 PM EDT
Completed Phase 2 Interventional Results available

Nirogacestat in Ovarian Granulosa Cell Tumors

NCT05348356
View directory record Official record
Conditions
Ovarian Granulosa-Stromal Tumor, Ovarian Granulosa Cell Tumor, Ovarian Cancer
Interventions
Nirogacestat
Drug
Lead sponsor
SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany
Industry
Eligibility
18 Years and older · Female only
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
16
States / cities
Los Angeles, California • Orlando, Florida • Tampa, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 20, 2026, 9:23 PM EDT
Completed Phase 1 Interventional

MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma

NCT00020579
View directory record Official record
Conditions
Cancer
Interventions
entinostat
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2008
U.S. locations
3
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 15, 2012 · Synced Oct 20, 2026, 9:23 PM EDT
Completed Phase 2 Interventional Results available

Combination Chemotherapy and Pegfilgrastim in Treating Patients With Previously Untreated Germ Cell Tumors

NCT00470366
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Extragonadal Germ Cell Tumor, Ovarian Cancer, Teratoma, Testicular Germ Cell Tumor
Interventions
pegfilgrastim, cisplatin, ifosfamide, paclitaxel
Biological · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 120 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2016
U.S. locations
2
States / cities
Los Angeles, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 28, 2017 · Synced Oct 20, 2026, 9:23 PM EDT
Completed Phase 2 Interventional Results available

Avastin +/- Erlotinib Consolidation Chemotherapy After Carboplatin, Paclitaxel, and Avastin (CTA) Induction Therapy for Advanced Ovarian, Fallopian Tube, Primary Peritoneal Cancer & Papillary Serous or Clear Cell Mullerian Tumors

NCT00520013
View directory record Official record
Conditions
Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Papillary Serous Mullerian Tumor, Clear Cell Mullerian Tumor
Interventions
bevacizumab, erlotinib, paclitaxel, carboplatin
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 27, 2018 · Synced Oct 20, 2026, 9:23 PM EDT
Active, not recruiting Phase 1 Interventional

Safety and Tolerability of IPH4502 in Patients With Advanced Solid Tumors

NCT06781983
View directory record Official record
Conditions
Advanced or Metastatic Solid Tumors
Interventions
IPH4502
Drug
Lead sponsor
Innate Pharma
Industry
Eligibility
18 Years and older
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
5
States / cities
Boston, Massachusetts • Hackensack, New Jersey • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Oct 20, 2026, 9:23 PM EDT
Completed Phase 1 Interventional

The Physiological Responses and Adaptation of Brown Adipose Tissue to Chronic Treatment With Beta3-Adrenergic Receptor Agonists

NCT03049462
View directory record Official record
Conditions
Polycystic Ovary Syndrome
Interventions
Mirabegron, B Complex Plus Vitamin C Tablets
Drug · Other
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 40 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 20, 2026, 9:23 PM EDT
Terminated Phase 1 Interventional

Study of Oncoimmunome for the Treatment of Stage III/IV Ovarian Carcinoma

NCT02933073
View directory record Official record
Conditions
Ovarian Cancer
Interventions
OncoImmunome
Biological
Lead sponsor
UConn Health
Other
Eligibility
18 Years and older · Female only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Farmington, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 7, 2022 · Synced Oct 20, 2026, 9:23 PM EDT
Completed No phase listed Observational

Microvascular Ultrasonographic Imaging for the Detection of Early Stage Epithelial Ovarian Carcinoma

NCT00531570
View directory record Official record
Conditions
Ovarian Neoplasms
Interventions
Not listed
Lead sponsor
NYU Langone Health
Other
Eligibility
21 Years and older · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 23, 2010 · Synced Oct 20, 2026, 9:23 PM EDT
Completed Phase 2 Interventional Results available

Study of Bevacizumab/Doxil in Treatment of Platinum-Resistant/Refractory Ovarian Cancer (CA)

NCT00945139
View directory record Official record
Conditions
Ovarian Cancer
Interventions
Doxil, Avastin
Drug
Lead sponsor
New Mexico Cancer Research Alliance
Other
Eligibility
18 Years and older · Female only
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
3
States / cities
Albuquerque, New Mexico • Santa Fe, New Mexico • New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 31, 2015 · Synced Oct 20, 2026, 9:23 PM EDT